WO2010017265A3 - Injectable extended release compositions containing an ion channel blocker for the treatment of arthritis - Google Patents

Injectable extended release compositions containing an ion channel blocker for the treatment of arthritis Download PDF

Info

Publication number
WO2010017265A3
WO2010017265A3 PCT/US2009/052796 US2009052796W WO2010017265A3 WO 2010017265 A3 WO2010017265 A3 WO 2010017265A3 US 2009052796 W US2009052796 W US 2009052796W WO 2010017265 A3 WO2010017265 A3 WO 2010017265A3
Authority
WO
WIPO (PCT)
Prior art keywords
arthritis
treatment
compositions containing
extended release
ion channel
Prior art date
Application number
PCT/US2009/052796
Other languages
French (fr)
Other versions
WO2010017265A2 (en
Inventor
Martin Becker
Original Assignee
Calosyn Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US8698308P priority Critical
Priority to US61/086,983 priority
Application filed by Calosyn Pharma filed Critical Calosyn Pharma
Publication of WO2010017265A2 publication Critical patent/WO2010017265A2/en
Publication of WO2010017265A3 publication Critical patent/WO2010017265A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Abstract

Provided herein are compositions, methods, and kits that include compositions suitable for intra- articular administration to a joint of a patient suffering from osteoarthritis and that include a biocompatible matrix; and at least one ion-channel regulator.
PCT/US2009/052796 2008-08-07 2009-08-05 Injectable extended release compositions and methods of treating arthritis using same WO2010017265A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US8698308P true 2008-08-07 2008-08-07
US61/086,983 2008-08-07

Publications (2)

Publication Number Publication Date
WO2010017265A2 WO2010017265A2 (en) 2010-02-11
WO2010017265A3 true WO2010017265A3 (en) 2011-09-29

Family

ID=41664181

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/052796 WO2010017265A2 (en) 2008-08-07 2009-08-05 Injectable extended release compositions and methods of treating arthritis using same

Country Status (1)

Country Link
WO (1) WO2010017265A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201532633A (en) 2013-03-21 2015-09-01 Eupraxia Pharmaceuticals USA LLC Injectable sustained release composition and method of using the same for treating inflammation in joints and pain associated therewith

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478848A (en) * 1994-01-26 1995-12-26 Bayer Corporation Inhibition of arthritis by L-type calcium channel antagonists nimodipine, nisoldipine and nifedipine
US5942241A (en) * 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US6221861B1 (en) * 1998-07-10 2001-04-24 The Regents Of The University Of California Reducing pyrophosphate deposition with calcium antagonists
WO2002076344A1 (en) * 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US20060270716A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Method for treating osteoarthritis
WO2009129531A2 (en) * 2008-04-18 2009-10-22 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060269579A1 (en) 2005-05-25 2006-11-30 Musculoskeletal Research Llc Compositions for treating osteoarthritis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478848A (en) * 1994-01-26 1995-12-26 Bayer Corporation Inhibition of arthritis by L-type calcium channel antagonists nimodipine, nisoldipine and nifedipine
US5942241A (en) * 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US6221861B1 (en) * 1998-07-10 2001-04-24 The Regents Of The University Of California Reducing pyrophosphate deposition with calcium antagonists
WO2002076344A1 (en) * 2001-03-23 2002-10-03 Durect Corporation Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space
US20060270716A1 (en) * 2005-05-25 2006-11-30 Musculoskeletal Research Llc Method for treating osteoarthritis
WO2009129531A2 (en) * 2008-04-18 2009-10-22 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier

Also Published As

Publication number Publication date
WO2010017265A2 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
CA2742821C (en) Modulators of atp-binding cassette transporters
JO2755B1 (en) Use of 2-6 (3- amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrilfor treating diabetes,cancer , autoimmune disorders and hiv infection
WO2011090760A4 (en) Heteroaryl compounds and uses thereof
SG189813A1 (en) Systems, methods and compositions for optical stimulation of target cells
CA2798622A1 (en) Indoles
TW201639852A (en) Intermediate compounds for preparation of compounds useful as modulators of toll-like receptors
TW200904439A (en) Pyridone GPR119 G protein-coupled receptor agonists
MX2011010169A (en) Bispecific anti-erbb-1/anti-c-met antibodies.
EA029502B1 (en) Super fast-acting insulin compositions
MX2009001982A (en) Titanium dioxide-containing composite.
AU2016204346A1 (en) Methods and compositions for cell-proliferation-related disorders
MX2011003133A (en) Bispecific anti-egfr/anti-igf-1r antibodies.
SG195536A1 (en) Bispecific anti-vegf/anti-ang-2 antibodies
WO2009073508A3 (en) Polysaccharide gel compositions and methods for sustained delivery of drugs
MY159955A (en) Certain chemical entities, compositions and methods
TW200908983A (en) Heterocyclic compounds and uses thereof
IN2012DN01961A (en) "heterocyclic compounds and uses thereof"
EA021176B1 (en) Polymorphic form of rifaximin and use thereof
TN2011000416A1 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2010069532A8 (en) Antibodies against human angiopoietin 2
AU2008222967A8 (en) Cross-linking of antioxidant-containing polymers
WO2010056754A3 (en) Inhibition of mammalian target of rapamycin
MX2011002966A (en) Pharmaceutical dosage forms comprising poly(e-caprolactone).
TW201529072A (en) Heteroaryl compounds and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09797211

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct app. not ent. europ. phase

Ref document number: 09797211

Country of ref document: EP

Kind code of ref document: A2